NSCLC cells with low RBL2 and high AURKA/B expression are largely resistant to NSCLC therapy reagents paclitaxel and radiation, and pharmacologic inhibition of AURKA/B or knockdown of AURKA/B pathway components sensitized cells to these agents. This evidence concerns the gene AURKA and non-small cell lung carcinoma.